Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

153.43 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,055
Open 153.43
Bid (Size) 153.09 (1)
Ask (Size) 153.20 (1)
Prev. Close 153.43
Today's Range 153.43 - 153.43
52wk Range 85.28 - 161.00
Shares Outstanding 57,152,295
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits. 
Via Benzinga
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Via Benzinga
Exposures Fossil Fuels

Performance

YTD
+20.31%
+20.31%
1 Month
+10.84%
+10.84%
3 Month
+26.16%
+26.16%
6 Month
+4.95%
+4.95%
1 Year
+60.49%
+60.49%

More News

Read More
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
Via Benzinga
Exposures Product Safety
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
Via Investor's Business Daily
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today
Via Benzinga
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Via Benzinga
Why Ascendis Pharma Stock Tumbled by 11% Today
Via The Motley Fool
Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout
Via Investor's Business Daily
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Via Benzinga
Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
Via Benzinga
(ASND) - Analyzing Ascendis Pharma's Short Interest
Via Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
Via Benzinga
Exposures Product Safety
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
Via Benzinga
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug
Via Investor's Business Daily
Exposures Product Safety
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
Via Benzinga
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
Via Benzinga
Exposures Product Safety
Masters In Trading - Saturday, May 11
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.